The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes

The Alzheimer's Disease Neuroimaging Initiative Phase 1 (ADNI‐1) is a multisite prospective study designed to examine potential cerebrospinal fluid and imaging markers of Alzheimer's disease (AD) and their relationship to cognitive change. The objective of this study was to provide a global summary of the overall results and patterns of change observed in candidate markers and clinical measures over the first 2 years of follow‐up.

[1]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[2]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[3]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[4]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[5]  Nick C Fox,et al.  Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations , 2010, European Radiology.

[6]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[7]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[8]  David A. Bennett,et al.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons , 2007, Neurology.

[9]  Robert Gray,et al.  Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis , 1992 .

[10]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[11]  R. Killiany,et al.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease , 2000, Annals of neurology.

[12]  Norbert Schuff,et al.  Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects , 2009, NeuroImage.

[13]  C R Jack,et al.  Imaging and Biomarkers in Early Alzheimer's Disease and Mild Cognitive Impairment , 2009, Clinical pharmacology and therapeutics.

[14]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[15]  Geert Molenberghs,et al.  Random Effects Models for Longitudinal Data , 2010 .

[16]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Jon A. Wellner,et al.  A Hybrid Algorithm for Computation of the Nonparametric Maximum Likelihood Estimator from Censored Data , 1997 .

[18]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[19]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[20]  M. Sarazin,et al.  Faculty Opinions recommendation of Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. , 2009 .

[21]  L. Schneider.  Assessing Outcomes in Alzheimer Disease , 2001, Alzheimer disease and associated disorders.

[22]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[23]  Michael W. Weiner,et al.  Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative , 2010, NeuroImage.

[24]  C. Jack,et al.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects , 2010, Alzheimer's & Dementia.

[25]  R. Kay.  The Analysis of Survival Data , 2012 .

[26]  Leslie M. Shaw,et al.  PENN Biomarker Core of the Alzheimer’s Disease Neuroimaging Initiative , 2007, Neurosignals.